Figure (1): Results of the analysis of PtNTT2 using Phobius.
The 30 first amino acids are clearly recognized as a signal peptide. Ten transmembrane domains are predicted.
Difference between revisions of "Team:Bielefeld-CeBiTec/Results/unnatural base pair/uptake and biosynthesis"
MarkusHaak (Talk | contribs) |
|||
Line 4: | Line 4: | ||
<body> | <body> | ||
<div class="container"> | <div class="container"> | ||
− | <div id="title" style="background-image: url(https://static.igem.org/mediawiki/2017/ | + | <div id="title" style="background-image: url(https://static.igem.org/mediawiki/2017/8/88/T--Bielefeld-CeBiTec--title-img-uptake.jpg);"> |
− | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/8/88/T--Bielefeld-CeBiTec--title-img-uptake.jpg"> |
<div id="title-bg"> | <div id="title-bg"> | ||
<div id="title-text"> | <div id="title-text"> |
Revision as of 15:30, 6 October 2017
Uptake and Biosynthesis
Computational Analysis of PtNTT2
Plasmid Design
Figure (2): Schematic overview of the design of the different transporter variants.
The lacUV5 promotor was used together with a strong RBS (BBa_B0034) for all parts. All variants except for pSB1C3-PtNTT2 were also tagged with GFP (BBa_E0040). cMyc was used as a linker (based on BBa_K2082221).